The six botulinum toxin type A products approved by the U.S. Food and Drug Administration (FDA) for aesthetic use are Botox®, Dysport®, Xeomin®, Jeuveau®, Daxxify®, and Letybo®. Although they all act by blocking acetylcholine release at the neuromuscular junction, they differ slightly in formulation, dosing equivalence, and regulatory indications.

Please note: All brand names are registered trademarks of their respective manufacturers. There is no “generic” botulinum toxin A approved for use on patients.

Key Facts About Botulinum Toxin Brands

All FDA-approved aesthetic botulinum toxin products work through the same mechanism: blocking acetylcholine release at the neuromuscular junction to temporarily relax targeted muscles.
Botox Cosmetic®, Dysport®, Xeomin®, Jeuveau®, Daxxify®, and Letybo® all produce broadly similar cosmetic results when appropriate dosing and injection technique are used.
Differences between toxin brands often relate more to marketing positioning, pricing strategies, and loyalty programs than to major pharmacologic distinctions.
Dysport® is commonly associated with a faster onset claim, Xeomin® emphasizes its “naked toxin” formulation, Jeuveau® focuses on modern branding, Daxxify® promotes extended duration with higher doses, and Letybo® has entered the U.S. market as a price-competitive option.
For most aesthetic providers, treatment outcomes depend far more on anatomy knowledge, dosing strategy, and injection technique than on the specific neuromodulator brand selected.

FDA-Approved Botulinum Toxins for Aesthetic Use (Comparison)

Category	Botox Cosmetic®	Dysport®	Xeomin®	Jeuveau®	Daxxify®	Letybo®
FDA Approval Year	2002	2009	2011	2019	2022	2024
Manufacturer	Allergan / AbbVie	Galderma	Merz	Evolus	Revance	Hugel
Active Toxin	OnabotulinumtoxinA	AbobotulinumtoxinA	IncobotulinumtoxinA	PrabotulinumtoxinA	DaxibotulinumtoxinA	LetibotulinumtoxinA
Accessory Proteins	Present	Present	None (naked toxin)	Present	Peptide stabilizer	Present
Typical Onset	3–5 days	2–4 days	3–5 days	3–5 days	3–4 days	3–5 days
Typical Duration	3–4 months	3–4 months	3–4 months	3–4 months	4-6 months (reported using 2-2.5x dose)	3–4 months
Conversion Ratio vs Botox	1:1	2.5–3:1 (different potency units)	1:1	1:1	not clearly established	1:1
FDA Approved Aesthetic Uses	Glabellar lines, crow’s feet, forehead, platysma bands	Glabellar lines	Glabellar lines	Glabellar lines	Glabellar lines	Glabellar lines
Storage	Refrigerated	Refrigerated	Room temp before reconstitution	Refrigerated	Refrigerated	Refrigerated
Immunogenicity Risk	Very low	Very low	Very low	Very low	Very low	Very low
Approximate Cost per 20u Botox Cosmetic® Equivalent Dose without volume discounts.	$$$	$$-$$$	$$-$$$	$$-$$$	$$-$$$	$-$$

Botox Cosmetic® Review

Botox® was the first botulinum toxin FDA approved for use in humans, receiving approval in 1989 for the treatment of facial muscle spasms rather than cosmetic indications. As off-label use for dynamic wrinkles of the upper face emerged during the 1990s, Botox Cosmetic® (onabotulinumtoxinA), manufactured by AbbVie/Allergan, became the first botulinum toxin type A product approved by the U.S. Food and Drug Administration (FDA) for aesthetic use. Initial approval for glabellar frown lines occurred in 2002, followed by approvals for lateral canthal lines (crow’s feet) in 2013, forehead lines in 2017, and platysma bands of the neck in 2024. These approvals made Botox Cosmetic® the first neuromodulator with four separate FDA-approved aesthetic treatment areas.¹ ²

Botox® works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted facial muscles and reducing dynamic wrinkles. Clinical onset typically occurs within three to five days, with maximal effect at approximately two weeks and a typical duration of three to four months for most aesthetic indications.¹

Botox® remains the most widely recognized botulinum toxin brand globally and is often used colloquially as a generic term for cosmetic neuromodulator injections. The brand has been used for more than two decades in aesthetic medicine, with more than 100 million vials distributed worldwide.³ Market analyses suggest that Botox® products continue to hold a dominant share of the neuromodulator market—approximately 60 percent in the United States—largely due to strong brand recognition and long-standing clinical experience.⁴

Demand for botulinum toxin procedures has also expanded substantially over the past two decades as minimally invasive cosmetic procedures have become more widely accepted. Millions of treatments are performed annually, and the global botulinum toxin market is projected to continue growing steadily over the coming decade as patient demand for non-surgical facial rejuvenation increases.⁵ ⁶ For many aesthetic practices, the strong public awareness of the Botox® brand can make it easier to introduce neuromodulator treatments to new patients compared with less familiar toxin products. It still has 55-65% market share for aesthetic toxin use in the USA.

AbbVie also supports Botox Cosmetic® with the Alle℠ loyalty and rewards program, which allows patients to accumulate points for aesthetic treatments and redeem them toward future procedures. The platform can help practices encourage repeat visits and maintain patient engagement with the brand and their injecting provider. Providers may also use the system to send promotional offers, reminders, and reactivation communications to existing patients.

References

Dysport® Review

Dysport® (abobotulinumtoxinA), manufactured by Ipsen and distributed in the United States by Galderma, was the second botulinum toxin type A product approved by the U.S. Food and Drug Administration (FDA) for aesthetic use. Dysport® received FDA approval in 2009 for the temporary improvement of moderate-to-severe glabellar lines in adult patients.¹ As the first major competitor to Botox Cosmetic®, Dysport® entered the aesthetic market with a similar mechanism of action but with differences in formulation and dosing units.

Like other botulinum toxin type A products, Dysport® works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted muscles responsible for dynamic facial wrinkles. Clinical onset typically occurs within two to three days for many patients, and some studies have suggested that Dysport® may demonstrate a slightly faster onset of action compared with onabotulinumtoxinA when equivalent clinical dosing is used.² However, overall duration of effect remains broadly similar to other neuromodulators, typically lasting approximately three to four months for most aesthetic indications.

One commonly discussed difference between Dysport® and Botox Cosmetic® is the unit conversion ratio. Dysport® units are not interchangeable with those of other botulinum toxin products, and clinical equivalence is often approximated at roughly 2.5–3 units of Dysport® for every 1 unit of Botox®.¹ Because of this difference in potency units, Dysport® treatments typically involve a larger numerical unit dose even though clinical outcomes are comparable. This distinction can sometimes create confusion for new injectors and patients when comparing treatment dosing between toxin brands.

Since its introduction, Dysport® has become one of the most widely used botulinum toxin products worldwide and remains a significant competitor in the neuromodulator market. The product is often marketed with claims of faster onset and broader diffusion characteristics, which some practitioners believe may allow for smoother results in larger treatment areas such as the forehead. However, when appropriate dosing and injection technique are used, clinical studies generally demonstrate similar safety and efficacy profiles among the currently approved botulinum toxin type A products.³ Over time, they have lost market share to newer entrants and currently enjoys around 10-15% aesthetic toxin market share.

Galderma supports Dysport® with educational programs and promotional initiatives aimed at aesthetic providers, although the brand does not currently offer a patient loyalty program with the same scale or consumer recognition as the Alle℠ platform used for Botox Cosmetic®. As a result, while Dysport® remains a popular neuromodulator among experienced injectors, the brand recognition among patients is often lower than that of Botox®, which continues to dominate consumer awareness in many markets.

References

Xeomin® Review

Xeomin® (incobotulinumtoxinA), manufactured by Merz, was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the temporary improvement of moderate-to-severe glabellar lines in adult patients.¹ Xeomin® entered the aesthetic market as the first widely used botulinum toxin type A product marketed as free of complexing, or accessory, proteins.² This “naked toxin” concept became the brand’s main scientific and marketing differentiator from Botox Cosmetic® and Dysport®.

Like other botulinum toxin type A products, Xeomin® works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted muscles that create dynamic facial wrinkles. Clinical studies have shown that Xeomin® produces efficacy and duration of effect comparable to other botulinum toxin type A products used for glabellar lines, with typical onset in the first several days after treatment and duration generally in the range of three to four months for most patients.³ Xeomin® units are generally treated as clinically comparable to Botox® units on a 1:1 basis in aesthetic practice, although, as with all botulinum toxin products, FDA labeling states that potency units are specific to each preparation and are not interchangeable.¹

Xeomin® is often promoted as a “purer” botulinum toxin because it contains the 150 kDa active neurotoxin without accessory proteins.² Published literature supports that incobotulinumtoxinA is free of complexing proteins and may have lower theoretical antigenic protein exposure than older botulinum toxin formulations.² ⁴ For that reason, Xeomin® is sometimes marketed as having a lower long-term risk of antibody formation or secondary nonresponse. However, in aesthetic dosing ranges, clinically meaningful immunogenicity is already uncommon across all currently approved botulinum toxin type A products, so this distinction may be scientifically interesting without creating a major day-to-day clinical advantage for most cosmetic patients.⁴ ⁵

Before reconstitution, Xeomin® is supplied as a sterile white to off-white lyophilized powder in a single-dose vial, a formulation detail specifically described in the FDA prescribing information.¹ In practice, some clinicians notice that Xeomin® may appear visually more substantial in the vial before saline is added, which reinforces the brand’s “pure product” identity, although this appearance does not by itself imply superior clinical performance. As with the other major neuromodulators, the most important determinants of outcome remain patient selection, dosing, anatomy, and injection technique rather than formulation appearance alone. When reconstituting Xeomin, one must be certain to invert the vial multiple times after adding the saline

Merz has positioned Xeomin® as a scientifically refined alternative to older toxin brands, particularly for providers who value the absence of accessory proteins and room-temperature storage of unopened vials.² ¹ At the same time, Xeomin® (approximately 8-10% market share) has generally not achieved the same level of consumer name recognition as Botox Cosmetic®, and it does not have a patient rewards ecosystem as visible or widely used as Alle℠. As a result, Xeomin® is well-respected among experienced providers and supported by published literature, but for most aesthetic practices its practical clinical differences from other type A toxins remain modest.

References

Jeuveau® Review

Jeuveau® (prabotulinumtoxinA-xvfs), manufactured by Evolus and produced by the South Korean pharmaceutical company Daewoong, was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the temporary improvement of moderate-to-severe glabellar lines in adults.¹ Jeuveau® entered the aesthetic market as the newest botulinum toxin type A competitor to Botox Cosmetic® and Dysport®, with a formulation and clinical performance that is broadly comparable to other neuromodulators already in use.

Like other botulinum toxin type A products, Jeuveau® works by blocking the presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening facial muscles responsible for dynamic wrinkles. Clinical trials demonstrated efficacy and duration similar to other neuromodulators used for glabellar lines, with onset typically occurring within several days and duration generally lasting about three to four months in most patients.² Jeuveau® dosing units are generally considered clinically comparable to Botox® units on a 1:1 basis in aesthetic practice, although, as with all botulinum toxin products, potency units are specific to each preparation and are not interchangeable according to FDA labeling.¹

Shortly after its launch, Jeuveau® became involved in a high-profile intellectual property dispute between Daewoong and Medytox, another South Korean botulinum toxin manufacturer. The dispute centered on allegations that Daewoong had misappropriated proprietary toxin strains during development of prabotulinumtoxinA. In 2020 the U.S. International Trade Commission initially ruled in favor of Medytox and issued a temporary import restriction on Jeuveau®.³ The companies later reached a settlement agreement that allowed continued distribution of Jeuveau® in the United States and other markets.⁴ While the litigation attracted industry attention, it did not ultimately prevent the product from remaining available to aesthetic providers.

Evolus positioned Jeuveau® with an unusually consumer-focused marketing strategy, sometimes referring to it as “Newtox” and promoting the product as a modern neuromodulator brand aimed at younger aesthetic patients. This messaging included the well-known description of Jeuveau® as “the toxin of millennials,” a phrase that generated both attention and skepticism among experienced providers. In clinical practice, however, Jeuveau® functions similarly to other botulinum toxin type A products, and most differences between toxins remain related to branding, pricing, and provider preference rather than large pharmacologic distinctions. This was the first toxin largely marketed directly to patients rather than providers. In 2025, the FDA warned Evolus about marketing tactics. Nothing about any product being “new” or “modern” has any effect on its efficacy in experienced providers’ hands.

Since its introduction, Jeuveau® has gained a modest but growing share of the neuromodulator market (around 10-15% at present), particularly among practices interested in a competitively priced alternative to Botox Cosmetic®. The product is supported by Evolus marketing programs and provider incentives, although it does not have the same level of consumer name recognition or loyalty ecosystem as the Alle℠ rewards program associated with Botox Cosmetic®. As with other botulinum toxin type A products, treatment outcomes ultimately depend far more on injection technique and dosing than on the specific toxin brand selected.

References

Daxxify® Review

Daxxify® (daxibotulinumtoxinA-lanm), manufactured by Revance Therapeutics, was approved by the U.S. Food and Drug Administration (FDA) in 2022 for the temporary improvement of moderate-to-severe glabellar lines in adult patients.¹ Daxxify® entered the aesthetic market as the first new botulinum toxin type A product approved in the United States in several years and was developed with a proprietary peptide stabilizing excipient designed to extend the duration of the neuromodulator’s clinical effect.

Like other botulinum toxin type A products, Daxxify® works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening facial muscles responsible for dynamic wrinkles. Clinical trials submitted for FDA approval demonstrated a median duration of effect of approximately six months for glabellar line treatment, which is longer than the three to four month duration commonly reported for earlier botulinum toxin products.² These studies generated significant interest in the possibility of longer-lasting neuromodulator treatments.

However, interpretation of these results requires consideration of dosing differences used in clinical trials. In pivotal studies supporting FDA approval, Daxxify® was typically administered at a 40-unit dose for glabellar lines, which is roughly double the commonly used 20-unit dose of Botox Cosmetic® in the same treatment area.² As a result, while Daxxify® may demonstrate longer duration in some patients, the higher dose requirements and higher per-unit pricing at launch raised questions among injectors about the overall cost-to-duration relationship compared with established neuromodulators.

Another distinctive feature of Daxxify® is its formulation technology. Unlike earlier toxins that rely on human serum albumin as a stabilizing protein, Daxxify® incorporates a proprietary peptide excipient intended to stabilize the neurotoxin molecule.³ This peptide technology is also part of the brand’s marketing narrative and has been suggested as one potential factor contributing to the extended duration observed in clinical trials. Nevertheless, real-world experience among injectors continues to evolve, and many clinicians report that treatment outcomes remain broadly similar to other neuromodulators when cost, dosing, and patient variability are considered.

Since its introduction, Daxxify® has gained attention for its longer-duration positioning but has not yet achieved widespread market penetration comparable to Botox®, Dysport®, or Xeomin®. Adoption has been gradual, with market share below 5%, as practices evaluate pricing structures, dosing strategies, and patient demand for extended-duration neuromodulator treatments. As with all botulinum toxin products, treatment outcomes ultimately depend far more on injection technique, patient anatomy, and dosing than on the specific toxin brand selected.

References

Letybo® Review

Letybo® (letibotulinumtoxinA-wlbg), manufactured by Hugel, received U.S. Food and Drug Administration (FDA) approval in 2024 for the temporary improvement of moderate-to-severe glabellar lines in adults.¹ Before entering the United States, the product had already been marketed extensively in South Korea (where it is currently the #1 selling botulinum toxin brand) under the name Botulax®, and in many international markets as Letybo®. Hugel describes Botulax® / Letybo® as its flagship botulinum toxin product and states that it is distributed in approximately 69 countries worldwide.^{2 3}

Like the other botulinum toxin type A products approved for aesthetic use, Letybo® works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted facial muscles that create dynamic wrinkles. In the pivotal clinical program reviewed by the FDA, Letybo® demonstrated efficacy and safety for glabellar lines with results broadly consistent with the established neuromodulator class.^{1 4} In everyday aesthetic use, Letybo® is generally discussed as a Botox®-like toxin with similar treatment goals, onset, and duration, rather than as a product with a dramatically different clinical profile.

One of the most important aspects of Letybo® is its commercial history outside the United States. In South Korea, Hugel and independent equity research have described Botulax® as the leading botulinum toxin brand, with one Korean research report estimating a 39 percent share of the domestic market in 2023.^{3 5} Hugel also describes itself as the market-leading injectable aesthetics company in South Korea and has repeatedly emphasized that Botulax® / Letybo® is its core growth product globally.^{2 6} That said, while the product clearly has broad international distribution and a strong position in Korea, publicly available sources were not sufficient to confirm that it is already the clear number two toxin worldwide by market share.

At launch in the United States, Letybo® was widely discussed as an aggressive price competitor. Hugel publicly stated that it intended to gain share through competitive pricing, and industry reporting suggested that the product would be offered below other established neuromodulators in the U.S. market.^{6 7} This price-first strategy is arguably one of the brand’s most meaningful differentiators. In contrast to some other toxins that primarily reward only high-volume accounts, Letybo® has been perceived by many providers as competing more directly on broad entry pricing. For practices that prioritize margin and affordability which can be passed along to patients, this may be more commercially meaningful than any subtle pharmacologic distinction between toxin brands.

Overall, Letybo® appears to be positioned less as a scientifically unique neuromodulator and more as a high-volume, globally established, price-competitive alternative to Botox® and the other U.S. toxins. Its long history in South Korea as Botulax®, combined with Hugel’s rapid international expansion, supports the view that it is an important new entrant rather than an experimental niche product.^{2 3 5 6} Even so, the broader conclusion remains the same: when proper dosing and injection technique are used, the practical clinical differences between the major botulinum toxin type A products are often modest.

References

Choosing the Right Botulinum Toxin

For new aesthetic providers entering the neuromodulator market, the differences between currently available botulinum toxin type A products are often more subtle than the marketing narratives surrounding them. Botox Cosmetic®, Dysport®, Xeomin®, Jeuveau®, Daxxify®, and Letybo® all work through the same basic mechanism—blocking presynaptic release of acetylcholine at the neuromuscular junction to temporarily weaken targeted facial muscles. When appropriate dosing and injection technique are used, clinical outcomes across these products are generally very similar for most cosmetic treatment areas.

Many of the distinctions highlighted by manufacturers—such as onset speed, duration, protein structure, or formulation technology—are scientifically interesting but often produce only modest differences in everyday clinical practice. As a result, the choice of neuromodulator frequently comes down to practical considerations such as brand recognition among patients, pricing structure, distributor support, and the responsiveness of local company representatives.

For providers evaluating which toxin to incorporate into their practice, one practical approach is to engage representatives from multiple manufacturers and evaluate the level of support offered to new accounts. Many companies provide educational resources, introductory pricing programs, or what are sometimes called “naïve patient” vials—essentially samples intended to help practices introduce new toxin brands or expand treatment areas for existing patients at a reduced cost.

One may encounter patients who insist that one toxin brand is better than another for them for a variety of reasons. However when queried, most will answer that the differing toxins treatments were designed and performed by different providers. This means that the person designing and performing the treatment was more likely to be the differentiator rather than the toxin brand. We currently do not have any reliable split face studies comparing toxin brands in equivalent unit dosages designed and performed by the same provider.

Ultimately, the most important determinants of patient satisfaction are not the specific toxin brand selected but the provider’s understanding of facial anatomy, appropriate dosing strategies, and precise injection technique. With proper training and experience, skilled injectors can achieve excellent cosmetic outcomes with any of the currently approved botulinum toxin type A products.

Botox® vs Dysport® vs Xeomin® vs Jeuveau® vs Daxxify® vs Letybo®: FDA-Approved Botulinum Toxin Comparison

Key Facts About Botulinum Toxin Brands

FDA-Approved Botulinum Toxins for Aesthetic Use (Comparison)

Botox Cosmetic® Review

References

Dysport® Review

References

Xeomin® Review

References

Jeuveau® Review

References

Daxxify® Review

References

Letybo® Review

References

Choosing the Right Botulinum Toxin